Search clinical trials for: TAK-783 and methotrexate

Total 4661 results

Millennium Pharmaceuticals, Inc.

Withdrawn

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Metastatic Melanoma | Advanced Non-hematologic Malignancies

United States
Takeda

Completed

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies

United States, Canada
Takeda

Completed

Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

Neuralgia, Postherpetic

Poland, United Kingdom, Germany, Bulgaria, Australia, Netherlands, Russian Federation, Czech Republic, South Africa
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys

Renal Impairment | Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

Healthy Volunteers

United States
Takeda

Recruiting

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Takeda

Completed

Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema

Hereditary Angioedema

Japan
Shire

Completed

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children (SPRING)

Hereditary Angioedema

United States, Canada, Germany, Hungary, Spain
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, Taiwan, Japan, China, Italy, Germany, United Kingdom, Puerto Rico
Shire
Takeda Development Center Americas, Inc.

Withdrawn

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

COVID-19 Pneumonia
Takeda

Completed

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

China
Takeda

Completed

An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063

Healthy Volunteers
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Angioedema

United States, France, Netherlands, Spain, Hungary, Italy, Canada, Poland, Japan, Germany
Shire

Completed

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
Takeda

Completed

Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid

Ukraine, Romania, Russian Federation, Slovakia, Latvia, Czech Republic
Takeda

Withdrawn

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Non-Small Cell Lung Cancer (NSCLC)
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Colorectal Cancer

Taiwan
St. Luke's-Roosevelt Hospital Center

Completed

Transplant and Addiction Project (TAP) - 1

Substance-Related Disorders | End Stage Liver Disease | End Stage Renal Disease

United States
University of Iceland
Uppsala University

Recruiting

The Lóa Study: A Brief Digital Intervention for Women With Intrusive Memories in the SAGA Cohort

Intrusive Memories of Traumatic Event(s)

Iceland
Kaohsiung Medical University Chung-Ho Memorial...

Unknown

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Taiwan
Takeda

Completed

TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants

Healthy

United Kingdom
Takeda

Active, not recruiting

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Japan
Takeda

Completed

A Study of TAK-105 in Healthy Adults

Healthy Volunteers

United States
Aptinyx
Massachusetts General Hospital; Premier Research Group plc

Completed

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Post-Traumatic Stress Disorder

United States
Shire
Takeda Development Center Americas, Inc.

No longer available

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Angioedema | Hereditary Angioedema (HAE)

United States, Canada, Germany, Hungary, Spain
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
Takeda

Completed

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

Phase 1, TAK-648, Single-Rising Dose Study

Healthy Volunteers
Takeda

Completed

A Study of TAK-510 in Healthy Adults

Healthy Participants

United States
Calithera Biosciences, Inc

Withdrawn

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Advanced Solid Neoplasms | Lymphoma Neoplasms
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

Healthy Volunteers

United States
Takeda

Terminated

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone

Low Testosterone

United States
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Takeda

Completed

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants

Autoimmune Disease

United Kingdom
Stanford University

Completed

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | KRAS Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
Takeda

Completed

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Healthy Volunteers

United States
Presage Biosciences
Takeda

Completed

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Head and Neck Cancer

United States
Unity Health Toronto

Recruiting

Endophthalmitis Post Intravitreal Injections (EPIIC)

Endophthalmitis

Canada
Takeda

Completed

Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid
Takeda

Completed

Phase III Study of Intramuscular TAK-816 in Healthy Infants

Healthy Volunteers | Haemophilus Influenzae Type b, Prevention

Japan
Takeda

Completed

A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects

Influenza

Japan

3

Subscribe